Molecularly organic/inorganic hybrid hollow mesoporous organosilica nanocapsules with tumor-specific biodegradability and enhanced chemotherapeutic functionality

Biomaterials. 2017 May:125:23-37. doi: 10.1016/j.biomaterials.2017.02.018. Epub 2017 Feb 15.

Abstract

Based on the intrinsic features of high stability and unique multifunctionality, inorganic nanoparticles have shown remarkable potentials in combating cancer, but their biodegradability and biocompatibility are still under debate. As a paradigm, this work successfully demonstrates that framework organic-inorganic hybridization can endow the inorganic mesoporous silica nanocarriers with unique tumor-sensitive biodegradability and high biocompatibility. Based on a "chemical homology" mechanism, molecularly organic-inorganic hybridized hollow mesoporous organosilica nanocapsules (HMONs) with high dispersity and sub-50 nm particle dimension were constructed in mass production. A physiologically active disulfide bond (SS) was directly incorporated into the silica framework, which could break up upon contacting the reducing microenvironment of tumor tissue and biodegrade accordingly. Such a tumor-specific biodegradability is also responsible for the tumor-responsive drug releasing by the fast biodegradation and disintegration of the framework. The ultrasmall particle size of HMONs guarantees their high accumulation into tumor tissue, thus causing the high chemotherapeutic outcome. This research provides a paradigm that framework organic-inorganic hybridization can endow the inorganic nanocarrier with unique biological effects suitable for biomedical application, benefiting the development of novel nanosystems with the unique bio-functionality and performance.

Keywords: Biodegradability; Cancer therapy; Drug delivery; Hollow; Mesoporous organosilica.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorbable Implants
  • Animals
  • Cell Line, Tumor
  • Delayed-Action Preparations / administration & dosage*
  • Delayed-Action Preparations / chemistry
  • Diffusion
  • Doxorubicin / administration & dosage*
  • Doxorubicin / chemistry
  • Drug Compounding / methods
  • Female
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Nanocapsules / administration & dosage
  • Nanocapsules / chemistry*
  • Nanocapsules / ultrastructure
  • Nanocomposites / administration & dosage
  • Nanocomposites / chemistry*
  • Nanocomposites / ultrastructure
  • Nanopores / ultrastructure
  • Neoplasms, Experimental / chemistry
  • Neoplasms, Experimental / drug therapy*
  • Neoplasms, Experimental / pathology
  • Particle Size
  • Porosity
  • Silicon Dioxide / administration & dosage
  • Silicon Dioxide / chemistry*
  • Treatment Outcome

Substances

  • Delayed-Action Preparations
  • Nanocapsules
  • Silicon Dioxide
  • Doxorubicin